Response to antiplatelet treatment: From genes to outcome

The Lancet

Volumn 376, Issue 9749, 2010, Pages 1278-1281

  Giusti, Betti ^a   Abbate, Rosanna ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; PRASUGREL; TICAGRELOR; ABCB1 PROTEIN, HUMAN; CYP2C19 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; BLEEDING; CORONARY ARTERY BYPASS GRAFT; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG METABOLISM; GENOTYPE; HUMAN; NOTE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; GENETICS; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CYTOCHROME P-450 CYP2C19; HUMANS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHARMACOGENETICS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; STENTS; THIOPHENES; TICLOPIDINE;

EID: 77958092237     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61313-X     Document Type: Note

References (19)

1. JL Anderson, CD Adams, EM Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 2007 e148 e304
2. FG Kushner, M Hand, SC Smith Jr 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
3. F Sofi, R Marcucci, AM Gori, B Giusti, R Abbate, GF Gensini Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis Thromb Haemost 103 2010 841 848
4. B Giusti, AM Gori, R Marcucci, R Abbate Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis Expert Opin Drug Metab Toxicol 6 2010 393 407
5. AR Shuldiner, JR O'Connell, KP Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
6. B Giusti, AM Gori, R Marcucci Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064
7. F Sofi, B Giusti, R Marcucci, AM Gori, R Abbate, GF Gensini Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis Pharmacogenomics J 2010 10.1038/tpj.2010.21 published online March 30.
8. JS Hulot, JP Collet, J Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
9. US Food and Drug Administration Plavix (clopidogrel bisulfate) 75 mg tablets http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm165166.htm May, 2009 (accessed Aug 23, 2010).
10. PA Gurbel, US Tantry Prasugrel, a third generation thienopyridine and potent platelet inhibitor Curr Opin Investig Drugs 9 2008 324 336
11. SD Wiviott, E Braunwald, CH McCabe for the TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
12. L Wallentin, RC Becker, A Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
13. JL Mega, SL Close, SD Wiviott Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 2010 10.1016/S0140-6736(10)61273-1 published online Aug 29.
14. L Wallentin, S James, RF Storey for the PLATO investigators Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 2010 10.1016/S0140-6736(10)61274-3 published online Aug 29.
15. T Simon, C Verstuyft, M Mary-Krause for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
16. D Taubert, N von Beckerath, G Grimberg Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501
17. A Owen, C Goldring, P Morgan, D Chadwick, BK Park, M Pirmohamed Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver Br J Clin Pharmacol 59 2005 365 370
18. S Hoffmeyer, O Burk, O von Richter Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 2000 3473 3538
19. SR Mehta, JP Bassand, S Chrolavicius on behalf of the CURRENT OASIS 7 Steering Committee Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy Am Heart J 156 2008 1080 1088.e1